Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Copycat versions of Eli Lilly's diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They're ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...

Not long ago, the FDA announced there's no longer a shortage of Ozempic, Wegovy, Zepbound or similar drugs used for weight ...

在其他近期新闻中，礼来已在印度推出其糖尿病和减肥药物Mounjaro，这是该国应对不断上升的肥胖和糖尿病率的重要一步。该药物有多种剂量可选，5毫克小瓶的价格为4,375卢比（50.67美元）。同时，Bernstein SocGen ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

The days of cheaper alternatives to popular weight-loss drugs like Wegovy and Zepbound are over for some Long Islanders and are numbered for others, pharmacists and compounding industry groups say.

(Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) This could end up making your wallet lighter if you are taking Ozempic or Zepbound for diabetes or weight loss. From 2024 to ...

The makers of weight-loss drugs Wegovy and Zepbound are lowering prices significantly, effective immediately, to make them more affordable.

Investing.com — 周一，UBS分析师Trung Huynh维持对礼来 (NYSE: LLY )股票的"中性"评级，目标价为1100美元。根据 InvestingPro ...

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...